Filing Flows › Stoke Therapeutics (STOK) › Q4 2025
Stoke Therapeutics (STOK) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 16, 2026
Stoke Therapeutics (STOK) reported revenue of $1.4M for the fourth quarter 2025 (Q4 2025), -94% from a year earlier and -87% from the quarter before.
Stoke Therapeutics, Q4 2025: revenue $1.4M (-94% year over year), net loss $57.9M, operating cash flow −$30.5M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.4M | -87% | -94% |
| Operating profit | −$61.4M | — | — |
| Net earnings | −$57.9M | — | — |
| Operating cash flow | −$30.5M | — | — |
What changed
Revenue was $1.4M in Q4 2025, down 94% year over year and down 87% from the previous quarter.
Operating costs exceeded revenue by $61.4M, an operating margin of -4382.2%. Total costs grew 73% against a revenue fall of 94%. The fastest-growing cost line was Research & development (+78%). The quarter ended with a net loss of $57.9M, wider than the previous quarter's $38.3M loss.
Operating cash flow was −$30.5M. Non-cash charges added back $405K of depreciation and $9.8M of share-based compensation. Working capital and other items added $17.2M. Capital expenditures of $232K exceeded it, leaving free cash flow of −$30.7M.
Questions
What was Stoke Therapeutics' revenue in the fourth quarter 2025?
Stoke Therapeutics (STOK) reported revenue of $1.4M for the fourth quarter 2025 (Q4 2025), -94% from a year earlier and -87% from the quarter before.
Source: Stoke Therapeutics 10-K on SEC EDGAR.